Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Intrinsic Value
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology... [ Read More ]
The intrinsic value of one JAZZ stock under the Base Case scenario is 336.97 USD. Compared to the current market price of 109.94 USD, Jazz Pharmaceuticals PLC is Undervalued by 67%.
Valuation Backtest
Jazz Pharmaceuticals PLC
Run backtest to discover the historical profit from buying and selling JAZZ stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Jazz Pharmaceuticals PLC
Current Assets | 3.4B |
Cash & Short-Term Investments | 1.6B |
Receivables | 855.1m |
Other Current Assets | 954m |
Non-Current Assets | 8B |
PP&E | 235m |
Intangibles | 7.2B |
Other Non-Current Assets | 551.8m |
Current Liabilities | 1.5B |
Accounts Payable | 102.8m |
Accrued Liabilities | 792.8m |
Other Current Liabilities | 641.1m |
Non-Current Liabilities | 6.1B |
Long-Term Debt | 5.1B |
Other Non-Current Liabilities | 1B |
Earnings Waterfall
Jazz Pharmaceuticals PLC
Revenue
|
3.8B
USD
|
Cost of Revenue
|
-435.6m
USD
|
Gross Profit
|
3.4B
USD
|
Operating Expenses
|
-2.7B
USD
|
Operating Income
|
659.4m
USD
|
Other Expenses
|
-244.5m
USD
|
Net Income
|
414.8m
USD
|
Free Cash Flow Analysis
Jazz Pharmaceuticals PLC
What is Free Cash Flow?
JAZZ Profitability Score
Profitability Due Diligence
Jazz Pharmaceuticals PLC's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Jazz Pharmaceuticals PLC's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
JAZZ Solvency Score
Solvency Due Diligence
Jazz Pharmaceuticals PLC's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Jazz Pharmaceuticals PLC's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JAZZ Price Targets Summary
Jazz Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for JAZZ is 192 USD with a low forecast of 122.21 USD and a high forecast of 241.5 USD.
Ownership
JAZZ Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
JAZZ Price
Jazz Pharmaceuticals PLC
Average Annual Return | 6.73% |
Standard Deviation of Annual Returns | 17.43% |
Max Drawdown | -43% |
Market Capitalization | 6.8B USD |
Shares Outstanding | 62 350 000 |
Percentage of Shares Shorted | 6.04% |
JAZZ News
Last Important Events
Jazz Pharmaceuticals PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Jazz Pharmaceuticals PLC
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 3,200 full-time employees. The company went IPO on 2012-01-18. The firm is focused on developing and commercializing products that address unmet medical needs. The firm has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The firm's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The firm also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Contact
IPO
Employees
Officers
The intrinsic value of one JAZZ stock under the Base Case scenario is 336.97 USD.
Compared to the current market price of 109.94 USD, Jazz Pharmaceuticals PLC is Undervalued by 67%.